ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
119.662,38
0,08%
S&P 500
5.431,60
-0,04%
US Dollar vs BRL
5,35049
0,00%
Bitcoin
66.500,14
0,47%
Brent Oil
82,275
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Silo Pharma Inc (SILO)

  7. Silo Pharma Inc (SILO) Notícias

SILO

Silo Pharma (SILO)

Silo Pharma Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:SILO
DataHoraFonteTítuloCódigoCompanhia
13/06/202418:08Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SILOSilo Pharma Inc
13/06/202414:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SILOSilo Pharma Inc
11/06/202417:00Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:SILOSilo Pharma Inc
07/06/202409:18GlobeNewswire Inc.Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for FibromyalgiaNASDAQ:SILOSilo Pharma Inc
06/06/202417:52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SILOSilo Pharma Inc
06/06/202417:50GlobeNewswire Inc.Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesNASDAQ:SILOSilo Pharma Inc
06/06/202407:07Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SILOSilo Pharma Inc
05/06/202409:00GlobeNewswire Inc.Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesNASDAQ:SILOSilo Pharma Inc
04/06/202409:41GlobeNewswire Inc.Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and AnxietyNASDAQ:SILOSilo Pharma Inc
21/05/202409:45GlobeNewswire Inc.Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse PreventionNASDAQ:SILOSilo Pharma Inc
14/05/202409:45GlobeNewswire Inc.Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in KetamineNASDAQ:SILOSilo Pharma Inc
13/05/202417:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SILOSilo Pharma Inc
23/04/202409:15GlobeNewswire Inc.Silo Pharma Announces Positive Results for Intranasal PTSD TreatmentNASDAQ:SILOSilo Pharma Inc
10/04/202409:11GlobeNewswire Inc.Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease TherapeuticNASDAQ:SILOSilo Pharma Inc
20/03/202409:30GlobeNewswire Inc.Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety TherapeuticNASDAQ:SILOSilo Pharma Inc
18/03/202408:15GlobeNewswire Inc.Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic PainNASDAQ:SILOSilo Pharma Inc
28/02/202410:25GlobeNewswire Inc.Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSDNASDAQ:SILOSilo Pharma Inc
14/02/202410:45GlobeNewswire Inc.Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug DeliveryNASDAQ:SILOSilo Pharma Inc
01/02/202412:00GlobeNewswire Inc.Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and NeurologyNASDAQ:SILOSilo Pharma Inc
31/01/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SILOSilo Pharma Inc
25/01/202419:29Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:SILOSilo Pharma Inc
25/01/202419:27Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SILOSilo Pharma Inc
24/01/202410:55GlobeNewswire Inc.Silo Pharma Announces Positive Results in Alzheimer’s Disease StudyNASDAQ:SILOSilo Pharma Inc
23/01/202419:01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SILOSilo Pharma Inc
11/01/202414:15Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:SILOSilo Pharma Inc
04/01/202410:55GlobeNewswire Inc.Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSDNASDAQ:SILOSilo Pharma Inc
28/12/202310:25GlobeNewswire Inc.Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for FibromyalgiaNASDAQ:SILOSilo Pharma Inc
20/12/202318:58Edgar (US Regulatory)Form 8-K12B - Notification that a class of securities of successor issuer is deemed to be registered pursuant to section 12(b)NASDAQ:SILOSilo Pharma Inc
21/11/202310:01GlobeNewswire Inc.Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSDNASDAQ:SILOSilo Pharma Inc
08/11/202310:11GlobeNewswire Inc.Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSDNASDAQ:SILOSilo Pharma Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:SILO

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
IDIV
Dividend
BOV
TOTS3
TOTVS ON
BOV
RRRP3
3R Petroleum Oleo E Gas ... ON
BOV
BPAC11
BTG PACTUAL UNT
BOV
BRBI11
BR PARTNERS UNT N2
BOV
CMIN3
CSN Mineracao S.A ON
BOV
HAGA3
HAGA ON
BOV
VVEO3
CM Hospitalar ON
BOV
PRIO3
PETRORIO ON
BOV
HBOR3
HELBOR ON
BOV
HOOT4
HOTEIS OTHON PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados